Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Covid19
Interventions
OTHER

Convalescent Plasma with antibody against SARS-CoV-2.

"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."

OTHER

Standard treatment for COVID-19

The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)

Trial Locations (1)

Unknown

University Hospital Son Llatzer, Palma de Mallorca

All Listed Sponsors
collaborator

Fundació d'investigació Sanitària de les Illes Balears

OTHER_GOV

lead

Hospital Son Llatzer

OTHER

NCT04803370 - Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma | Biotech Hunter | Biotech Hunter